Charles Schwab’s Lisata Therapeutics LSTA Stock Holding History

Charles Schwab’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,372	Closed	-$40K	–	3484
2021 Q1	$40K	Buy	+1,372	New	+$41.6K	﹤0.01%	3461
2015 Q2	–	Sell	-231	Closed	-$89K	–	3107
2015 Q1	$89K	Hold	231	–	–	﹤0.01%	3043
2014 Q4	$131K	Hold	231	–	–	﹤0.01%	3041
2014 Q3	$192K	Hold	231	–	–	﹤0.01%	2960
2014 Q2	$227K	Buy	+231	New	+$225K	﹤0.01%	2961

Other funds holding LSTA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Charles Schwab's LSTA Position: Q2 2021 in Review

Charles Schwab sold out of Lisata Therapeutics (LSTA) in Q2 2021, closing a stake of 1,372 shares — an estimated $40K sold.

Charles Schwab first reported a position in LSTA in Q2 2014 and held it in 5 quarters. The position peaked at $227K in Q2 2014. 27 funds tracked by Wall St. Rank hold LSTA as of Q2 2021.

Charles Schwab reported no remaining Lisata Therapeutics position as of Q2 2021 after selling out during the quarter.
Charles Schwab sold 1,372 Lisata Therapeutics shares in Q2 2021, an estimated $40K.
Charles Schwab first reported a position in Lisata Therapeutics in Q2 2014 and held it in 5 quarters.
Charles Schwab's Lisata Therapeutics position peaked at $227K in Q2 2014.
27 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.